Haemonetics price target raised to $93 from $90 at Barrington

Group 1 - Barrington raised the price target on Haemonetics (HAE) to $93 from $90, maintaining an Outperform rating on the shares [1] - The increase in price target is based on a positive view of Haemonetics' acquisition of Vivasure Medical Limited, an Ireland-based developer of advanced polymer implants and delivery systems [1]